This database contains 21 studies, archived under the term: "tau proteins"
Click here to filter this large number of results.
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
Stoeck, K.,
Sanchez-Juan, P.,
Gawinecka, J.,
Green, A.,
Ladogana, A.,
Pocchiari, M.,
Sanchez-Valle, R.,
Mitrova, E.,
Sklaviadis, T.,
Kulczycki, J.,
Slivarichova, D.,
Saiz, A.,
Calero, M.,
Knight, R.,
Aguzzi, A.,
Laplanche, J.-L.,
Peoc'h, K.,
Schelzke, G.,
Karch, A.,
van Duijn, C. M.,
Zerr, I.
To date, cerebrospinal fluid analysis, particularly protein 14-3-3 testing, presents an important approach in the identification of Creutzfeldt-Jakob disease cases. However, one special point of criticism of 14-3-3 testing is the specificity in the differential diagnosis of rapid dementia. The constant observation of increased cerebrospinal fluid referrals in the national surveillance centres over the last […]
Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry
Skillbäck, Tobias,
Rosén, Christoffer,
Asztely, Fredrik,
Mattsson, Niklas,
Blennow, Kaj,
Zetterberg, Henrik
Importance: Identifying a clinical distinction between the invariably lethal prion disease Creutzfeldt-Jakob disease (CJD) and nonprion rapidly progressive dementias is important and sometimes difficult; thus, reliable tools for diagnosis are in great demand.; Objective: To test the diagnostic performance of dementia cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), and the T-tau to […]
Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death
Sierra, Saleta,
Ramos, Maria C.,
Molina, Pilar,
Esteo, Cynthia,
Vázquez, Jose Antonio,
Burgos, Javier S.
There is growing evidence to support the hypothesis that statins may act as neuroprotectants in several neuropathological conditions, including Alzheimer’s disease. The mechanisms for neuroprotection are only partially understood, however, and pleiotropic phenomena could be involved. We have made a comparative study of 9 statins (lovastatin, mevastatin, pravastatin, simvastatin, cerivastatin, atorvastatin, fluvastatin, pitavastatin, and rosuvastatin), […]
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Shaw, Leslie M.,
Vanderstichele, Hugo,
Knapik-Czajka, Malgorzata,
Figurski, Michal,
Coart, Els,
Blennow, Kaj,
Soares, Holly,
Simon, Adam J.,
Lewczuk, Piotr,
Dean, Robert A.,
Siemers, Eric,
Potter, William,
Lee, Virginia M.-Y.,
Trojanowski, John Q.
The close correlation between abnormally low pre-mortem cerebrospinal fluid (CSF) concentrations of amyloid-β1-42 (Aβ(1-42)) and plaque burden measured by amyloid imaging as well as between pathologically increased levels of CSF tau and the extent of neurodegeneration measured by MRI has led to growing interest in using these biomarkers to predict the presence of AD plaque […]
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice
Sauvée, Mathilde,
DidierLaurent, Guerric,
Latarche, Clotilde,
Escanyé, Marie-Christine,
Olivier, Jean-Luc,
Malaplate-Armand, Catherine
Background: Cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for the diagnosis of Alzheimer’s disease (AD). Since interpretation of CSF profile requires the combination of three parameters, biological data are not always conclusive and isolated elevation of phosphorylated tau (P-tau) or reduction of amyloid-β (Aβ)42 alone can be observed. In these cases, […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
Application of immunosignatures to the assessment of Alzheimer’s disease
Objective: Accurate assessment of Alzheimer’s disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may […]
Comparison of two analytical platforms for the clinical qualification of Alzheimer’s disease biomarkers in pathologically-confirmed dementia
Le Bastard, Nathalie,
Coart, Els,
Vanderstichele, Hugo,
Vanmechelen, Eugeen,
Martin, Jean-Jacques,
Engelborghs, Sebastiaan
Combined analysis of the Alzheimer’s disease (AD) biomarkers amyloid-β(1-42) (Aβ(1-42)), total tau (T-tau), and hyperphosphorylated tau (P-tau(181P)) in cerebrospinal fluid (CSF) reduces the uncertainty associated with clinical dementia diagnosis. The present study evaluated the diagnostic accuracy of the CSF biomarker concentrations obtained with a multi-analyte Luminex assay (INNO-BIA AlzBio3) in comparison to single-analyte ELISA tests […]
Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)
Buerger, Katharina,
Frisoni, Giovanni,
Uspenskaya, Olga,
Ewers, Michael,
Zetterberg, Henrik,
Geroldi, Cristina,
Binetti, Giuliano,
Johannsen, Peter,
Rossini, Paolo Maria,
Wahlund, Lars-Olof,
Vellas, Bruno,
Blennow, Kaj,
Hampel, Harald
Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]
A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy
Borroni, Barbara,
Malinverno, Matteo,
Gardoni, Fabrizio,
Grassi, Mario,
Parnetti, Lucilla,
Agosti, Chiara,
Alberici, Antonella,
Premi, Enrico,
Bonuccelli, Ubaldo,
Gasparotti, Roberto,
Calabresi, Paolo,
Di Luca, Monica,
Padovani, Alessandro
Cerebrospinal fluid (CSF) tau ratio decrease (33kDa/55kDa forms) and mid-saggital midbrain-to-pons (MP) atrophy have been suggested as diagnostic markers for progressive supranuclear palsy (PSP). The usefulness of their combined evaluation has never been tested. We evaluated the CSF tau ratio and the MP atrophy as a combined marker for early identification of PSP. A total […]